SLNO · As filed with the SEC
Soleno Therapeutics balance sheet, by fiscal year
The statement as Soleno Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 | FY2020 Dec 31, 2020 | FY2019 Dec 31, 2019 | FY2018 Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | 70,106,000 | 87,928,000 | 169,681,000 | 14,602,000 | 21,304,000 | 49,224,000 | 20,733,000 | 23,099,000 |
| Marketable securities | 235,366,000 | 203,509,000 | — | — | — | — | — | — |
| Accounts receivable, net | 28,208,000 | — | — | — | — | — | — | — |
| Inventory, net | 15,024,000 | — | — | — | — | — | — | — |
| Prepaid expenses and other current assets | 7,110,000 | 2,452,000 | 1,677,000 | 1,045,000 | 1,118,000 | 1,019,000 | 411,000 | 529,000 |
| Due from related party | — | — | — | — | — | — | — | 64,000 |
| Minority interest investment in former subsidiary | — | — | — | — | — | — | — | 978,000 |
| Total current assets | 355,814,000 | 293,889,000 | 171,358,000 | 15,647,000 | 22,422,000 | 50,243,000 | 21,144,000 | 24,670,000 |
| Long-term assets | ||||||||
| Property and equipment, net | 185,000 | 186,000 | 12,000 | 26,000 | 33,000 | 19,000 | 22,000 | 12,000 |
| Operating lease right-of-use assets | 2,191,000 | 2,798,000 | 407,000 | 131,000 | 421,000 | 124,000 | 398,000 | — |
| Finance lease right-of-use assets | — | — | — | — | — | 15,000 | 24,000 | — |
| Intangible assets, net | 4,861,000 | 6,805,000 | 8,749,000 | 10,693,000 | 12,637,000 | 14,581,000 | 16,525,000 | 18,469,000 |
| Long-term marketable securities | 200,616,000 | 27,211,000 | — | — | — | — | — | — |
| Other long-term assets | 163,000 | 83,000 | 165,000 | — | 40,000 | — | 59,000 | — |
| Total assets | 563,830,000 | 330,972,000 | 180,691,000 | 26,497,000 | 35,553,000 | 64,982,000 | 38,172,000 | 43,151,000 |
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | 12,435,000 | 8,882,000 | 3,149,000 | 1,777,000 | 3,254,000 | 3,489,000 | 1,995,000 | 934,000 |
| Accrued compensation and other current liabilities | — | — | — | — | — | — | — | 943,000 |
| Accrued compensation | 9,677,000 | 4,776,000 | 3,135,000 | 1,675,000 | 728,000 | 1,005,000 | 283,000 | — |
| Accrued clinical trial site costs | — | 1,826,000 | 3,393,000 | 3,222,000 | 3,420,000 | 3,789,000 | 1,999,000 | — |
| Operating lease liabilities | 726,000 | 526,000 | 273,000 | 155,000 | 282,000 | 139,000 | 305,000 | — |
| Contingent liability for Essentialis purchase price | 20,327,000 | — | — | — | — | — | — | — |
| Other current liabilities | 18,198,000 | 2,737,000 | 1,555,000 | 484,000 | 323,000 | 196,000 | 382,000 | — |
| Total current liabilities | 61,363,000 | 18,747,000 | 11,505,000 | 7,313,000 | 8,007,000 | 8,618,000 | 4,964,000 | 1,877,000 |
| Long-term liabilities | ||||||||
| Series A Warrant Liability | — | — | — | — | — | — | — | 49,000 |
| 2017 PIPE Warrant | — | — | — | — | — | — | 10,822,000 | 4,563,000 |
| 2018 PIPE Warrants | — | — | 0 | 1,000 | 31,000 | 539,000 | 1,354,000 | 600,000 |
| Series C Warrant | — | — | — | — | — | — | — | 0 |
| Contingent liability for Essentialis purchase price | — | — | — | — | — | 10,278,000 | 5,938,000 | 5,649,000 |
| Contingent liability for Essentialis purchase price | — | 14,791,000 | 11,549,000 | 8,835,000 | 9,547,000 | — | — | — |
| Long-term debt, net | 49,863,000 | 49,828,000 | — | — | — | — | — | — |
| Long-term lease liabilities | 1,964,000 | 2,472,000 | 130,000 | 0 | 175,000 | — | — | — |
| Other long-term liabilities | 525,000 | 21,000 | — | — | — | — | 147,000 | — |
| Total liabilities | 113,715,000 | 85,859,000 | 23,184,000 | 16,149,000 | 17,760,000 | 19,435,000 | 23,225,000 | 12,738,000 |
| Stockholders’ equity | ||||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized, 52,286,881 and 45,703,811 shares issued and outstanding at December 31, 2025 and 2024, respectively | 52,000 | 46,000 | 32,000 | 8,000 | 80,000 | 80,000 | 45,000 | 32,000 |
| Additional paid-in-capital | 881,018,000 | 696,966,000 | 433,885,000 | 247,762,000 | 231,068,000 | 227,912,000 | 172,708,000 | 157,413,000 |
| Accumulated other comprehensive income | 415,000 | 361,000 | — | — | — | — | — | — |
| Accumulated deficit | (431,370,000) | (452,260,000) | (276,410,000) | (237,422,000) | (213,355,000) | (182,445,000) | (157,806,000) | (127,032,000) |
| Total stockholders' equity | 450,115,000 | 245,113,000 | 157,507,000 | 10,348,000 | 17,793,000 | 45,547,000 | 14,947,000 | 30,413,000 |
| Total liabilities and stockholders'equity | 563,830,000 | 330,972,000 | 180,691,000 | 26,497,000 | 35,553,000 | 64,982,000 | 38,172,000 | 43,151,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.